Rethinking peptide supply to MHC class I molecules

Nature Reviews Immunology

Volumn 7, Issue 5, 2007, Pages 403-410

  Eisenlohr, Laurence C ^a   Huang, Lan ^a   Golovina, Tania N ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; EPITOPE; HEAT SHOCK PROTEIN; HEMOGLOBIN; JANUS KINASE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MUTANT PROTEIN; PEPTIDE; PREALBUMIN; PROTEASOME INHIBITOR; PROTEIN S; SMAD4 PROTEIN; SUPEROXIDE DISMUTASE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

IN VITRO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR MODEL; MOLECULAR RECOGNITION; MOLECULE; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN QUALITY; PROTEIN SYNTHESIS; REVIEW;

ANIMALS; ANTIGEN PRESENTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MODELS, IMMUNOLOGICAL; PEPTIDES;

EID: 34247585533     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2077     Document Type: Review

References (90)

1. Cresswell, P., Ackerman, A. L., Giodini, A., Peaper, D. R. & Wearsch, P. A. Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol. Rev. 207, 145-157 (2005).
2. Groothuis, T. & Neefjes, J. The ins and outs of intracellular peptides and antigen presentation by MHC class I molecules. Curr. Top. Microbiol. Immunol. 300, 127-148 (2005).
3. van der Bruggen, P. & Van den Eynde, B. J. Processing and presentation of tumor antigens and vaccination strategies. Curr. Opin. Immunol. 18, 98-104 (2006).
4. + T cell cross-priming via transfer of proteasome substrates. Science 304, 1318-1321 (2004).
5. Donohue, K. B. et al. Cross-priming utilizes antigen not available to the direct presentation pathway. Immunology 119, 63-73 (2006).
6. Yewdell, J. W., Antón, L. C. & Bennink, J. R. Defective ribosomal products (DRIPs): a major source of antigenic peptides for MHC class I molecules? J. Immunol. 157, 1823-1826 (1996).
7. 91 Leu→Pro). J. Biol. Chem. 248, 7473-7480 (1973).
8. Adams, J. G. 3rd, Winter, W. P., Rucknagel, D. L. & Spencer, H. H. Biosynthesis of hemoglobin Ann Arbor: evidence for catabolic and feedback regulation. Science 176, 1427-1429 (1972).
9. 32 leu→pro). Blood 43, 657-664 (1974).
10. Rieder, R. F., Wolf, D. J., Clegg, J. B. & Lee, S. L. Rapid postsynthetic destruction of unstable haemoglobin Bushwick. Nature 254, 725-727 (1975).
11. Goldberg, A. L. Degradation of abnormal proteins in Escherichia coli (protein breakdown-protein structure-mistranslation-amino acid analogs-puromycin). Proc. Natl Acad. Sci. USA 69, 422-426 (1972).
12. Kemshead, J. T. & Hipkiss, A. R. Degradation of abnormal proteins in Escherichia coli: relative susceptibility of canavanyl proteins and puromycin peptides to proteolysis in vitro. Eur. J. Biochem. 45, 535-540 (1974).
13. Knowles, S. E., Gunn, J. M., Hanson, R. W. & Ballard, F. J. Increased degradation rates of protein synthesized in hepatoma cells in the presence of amino acid analogues. Biochem. J. 146, 595-600 (1975).
14. Wheatley, D. N., Giddings, M. R. & Inglis, M. S. Kinetics of degradation of 'short-' and 'long-lived' proteins in cultured mammalian cells. Cell Biol. Int. Rep. 4, 1081-1090 (1980).
15. Schubert, U. et al. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404, 770-774 (2000).
16. Bulik, S., Peters, B. & Holzhutter, H. G. Quantifying the contribution of defective ribosomal products to antigen production: a model-based computational analysis. J. Immunol. 175, 7957-7964 (2005).
17. Vabulas, R. M. & Hartl, F. U. Protein synthesis upon acute nutrient restriction relies on proteasome function. Science 310, 1960-1963 (2005).
18. Yewdell, J. W. & Nicchitta, C. V. The DRiP hypothesis decennial: support, controversy, refinement and extension. Trends Immunol. 27, 368-373 (2006).
19. Wherry, E. J., Puorro, K. A., Porgador, A. & Eisenlohr, L. C. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J. Immunol. 163, 3735-3745 (1999).
20. Townsend, A. et al. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J. Exp. Med. 168, 1211-1224 (1988).
21. Varshavsky, A. The N-end rule. Cell 69, 725-735 (1992).
22. Yewdell, J. W. The seven dirty little secrets of major histocompatibility complex class I antigen processing. Immunol. Rev. 207, 8-18 (2005).
23. Reits, E. A., Vos, J. C., Gromme, M. & Neefjes, J. The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature 404, 774-778 (2000).
24. Princiotta, M. F. et al. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 18, 343-354 (2003).
25. Turner, G. C. & Varshavsky, A. Detecting and measuring cotranslational protein degradation in vivo. Science 289, 2117-2120 (2000).
26. Ellis, R. J. & Minton, A. P. Cell biology: join the crowd. Nature 425, 27-28 (2003).
27. Dobson, C. M. & Karplus, M. The fundamentals of protein folding: bringing together theory and experiment. Curr. Opin. Struct. Biol. 9, 92-101 (1999).
28. Ellis, R. J. & Hartl, F. U. Principles of protein folding in the cellular environment. Curr. Opin. Struct. Biol. 9, 102-110 (1999).
29. Wickner, S., Maurizi, M. R. & Gottesman, S. Posttranslational quality control: folding, refolding, and degrading proteins. Science 286, 1888-1893 (1999).
30. Frydman, J. Folding of newly translated proteins in vivo: the role of molecular chaperones. Annu. Rev. Biochem. 70, 603-647 (2001).
31. Markossian, K. A. & Kurganov, B. I. Protein folding, misfolding, and aggregation. Formation of inclusion bodies and aggresomes. Biochemistry Mosc. 69, 971-984 (2004).
32. Lee, S. & Tsai, F. T. Molecular chaperones in protein quality control. J. Biochem. Mol. Biol. 38, 259-265 (2005).
33. Stefani, M. & Dobson, C. M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 81, 678-699 (2003).
34. Esser, C., Alberti, S. & Hohfeld, J. Cooperation of molecular chaperones with the ubiquitin/proteasome system. Biochim. Biophys. Acta 1695, 171-188 (2004).
35. Haslbeck, M., Franzmann, T., Weinfurtner, D. & Buchner, J. Some like it hot: the structure and function of small heat-shock proteins. Nature Struct. Mol. Biol. 12, 842-846 (2005).
36. Maier, T., Ferbitz, L., Deuerling, E. & Ban, N. A cradle for new proteins: trigger factor at the ribosome. Curr. Opin. Struct. Biol. 15, 204-212 (2005).
37. Wegrzyn, R. D. & Deuerling, E. Molecular guardians for newborn proteins: ribosome-associated chaperones and their role in protein folding. Cell. Mol. Life Sci. 62, 2727-2738 (2005).
38. Wegrzyn, R. D. et al. A conserved motif is prerequisite for the interaction of NAC with ribosomal protein L23 and nascent chains. J. Biol. Chem. 281, 2847-2857 (2006).
39. Otto, H. et al. The chaperones MPP11 and Hsp70L1 form the mammalian ribosome-associated complex. Proc. Natl Acad. Sci. USA 102, 10064-10069 (2005).
40. True, H. L. The battle of the fold: chaperones take on prions. Trends Genet. 22, 110-117 (2006).
41. Lim, W. K., Shin, H. J., Milton, D. L. & Hardman, J. K. Relative activities and stabilities of mutant Escherichia coli tryptophan synthase ? subunits. J. Bacteriol. 173, 1886-1893 (1991).
42. Hou, W. S. et al. Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis. J. Clin. Invest. 103, 731-738 (1999).
43. Schestag, F. et al. The functional consequences of mis-sense mutations affecting an intra-molecular salt bridge in arylsulphatase A. Biochem. J. 367, 499-504 (2002).
44. Jiang, H., Rao, K. S., Yee, V. C. & Kraus, J. P. Characterization of four variant forms of human propionyl-CoA carboxylase expressed in Escherichia coli. J. Biol. Chem. 280, 27719-27727 (2005).
45. Golovina, T. N., Morrison, S. E. & Eisenlohr, L. C. The impact of misfolding versus targeted degradation on the efficiency of the MHC class I-restricted antigen processing. J. Immunol. 174, 2763-2769 (2005).
46. Gileadi, U. et al. Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein. J. Immunol. 163, 6045-6052 (1999).
47. Wong, S. B., Buck, C. B., Shen, X. & Siliciano, R. F. An evaluation of enforced rapid proteasomal degradation as a means of enhancing vaccine-induced CTL responses. J. Immunol. 173, 3073-3083 (2004).
48. Uversky, V. N. Protein folding revisited. A polypeptide chain at the folding-misfolding-nonfolding cross-roads: which way to go? Cell. Mol. Life Sci. 60, 1852-1871 (2003).
49. Ward, C. L., Omura, S. & Kopito, R. R. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83, 121-127 (1995).
50. Farinha, C. M. & Amaral, M. D. Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin. Mol. Cell. Biol. 25, 5242-5252 (2005).
51. Choi, M. Y. et al. Destabilization of the transmembrane domain induces misfolding in a phenotypic mutant of cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 280, 4968-4974 (2005).
52. Klemes, Y., Etlinger, J. D. & Goldberg, A. L. Properties of abnormal proteins degraded rapidly in reticulocytes. Intracellular aggregation of the globin molecules prior to hydrolysis. J. Biol. Chem. 256, 8436-8444 (1981).
53. Wojcik, C. & DeMartino, G. N. Intracellular localization of proteasomes. Int. J. Biochem. Cell Biol. 35, 579-589 (2003).
54. Bukau, B., Weissman, J. & Horwich, A. Molecular chaperones and protein quality control. Cell 125, 443-451 (2006).
55. Qian, S. B., Princiotta, M. F., Bennink, J. R. & Yewdell, J. W. Characterization of rapidly degraded polypeptides in mammalian cells reveals a novel layer of nascent protein quality control. J. Biol. Chem. 281, 392-400 (2006).
56. Hayashi, S.-i., Murakami, Y. & Matsufuji, S. Ornithine decarboxylase antizyme: a novel type of regulatory protein. Trends Biochem. Sci. 21, 27-30 (1996).
57. Hipp, M. S., Kalveram, B., Raasi, S., Groettrup, M. & Schmidtke, G. FAT10, a ubiquitin-independent signal for proteasomal degradation. Mol. Cell. Biol. 25, 3483-3491 (2005).
58. Asher, G., Bercovich, Z., Tsvetkov, P., Shaul, Y. & Kahana, C. 20S proteasomal degradation of ornithine decarboxylase is regulated by NQO1. Mol. Cell 17, 645-655 (2005).
59. Petropoulos, L. & Hiscott, J. Association between HTLV-1 Tax and IκBα is dependent on the IκBα phosphorylation state. Virology 252, 189-199 (1998).
60. Orlowski, M. & Wilk, S. Ubiquitin-independent proteolytic functions of the proteasome. Arch. Biochem. Biophys. 415, 1-5 (2003).
61. Touitou, R. et al. A degradation signal located in the C-terminus of p21WAF1/CIP1 is a binding site for the C8 α-subunit of the 20S proteasome. EMBO J. 20, 2367-2375 (2001).
62. Cho, S. et al. Binding and regulation of HIF-1α by a subunit of the proteasome complex, PSMA7. FEBS Lett. 498, 62-66 (2001).
63. Yano, M., Koumoto, Y., Kanesaki, Y., Wu, X. & Kido, H. 20S proteasome prevents aggregation of heat-denatured proteins without PA700 regulatory subcomplex like a molecular chaperone. Biomacromolecules 5, 1465-1469 (2004).
64. Yano, M., Kanesaki, Y., Koumoto, Y., Inoue, M. & Kido, H. Chaperone activities of the 26S and 20S proteasome. Curr. Protein Pept. Sci. 6, 197-203 (2005).
65. Qian, S. B. et al. Tight linkage between translation and MHC class I peptide ligand generation implies specialized antigen processing for defective ribosomal products. J. Immunol. 177, 227-233 (2006).
66. Mayer, M. P., Brehmer, D., Gassler, C. S. & Bukau, B. Hsp70 chaperone machines. Adv. Protein Chem. 59, 1-44 (2001).
67. Patzelt, H. et al. Three-state equilibrium of Escherichia coli trigger factor. Biol. Chem. 383, 1611-1619 (2002).
68. Rauch, T. et al. Dissecting functional similarities of ribosome-associated chaperones from Saccharomyces cerevisiae and Escherichia coli. Mol. Microbiol. 57, 357-365 (2005).
69. Wheatley, D. N. Intracellular protein degradation: basis of a self-regulating mechanism for the proteolysis of endogenous proteins. J. Theor. Biol. 107, 127-149 (1984).
70. Antón, L. C. et al. Intracellular localization of proteasomal degradation of a viral antigen. J. Cell. Biol. 146, 113-124 (1999).
71. Hickman, H. D. et al. Toward a definition of self: proteomic evaluation of the class I peptide repertoire. J. Immunol. 172, 2944-2952 (2004).
72. Bacík, I. et al. Introduction of a glycosylation site into a secreted protein provides evidence for an alternative antigen processing pathway: transport of precursors of MHC class I restricted-peptides from the endoplasmic reticulum to the cytosol. J. Exp. Med. 186, 479-487 (1997).
73. Mosse, C. A. et al. The class I antigen-processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosol. J. Exp. Med. 187, 37-48 (1998).
74. Meusser, B., Hirsch, C., Jarosch, E. & Sommer, T. ERAD: the long road to destruction. Nature Cell Biol. 7, 766-772 (2005).
75. Oyadomari, S. et al. Cotranslocational degradation protects the stressed endoplasmic reticulum from protein overload. Cell 126, 727-739 (2006).
76. Hanada, K., Yewdell, J. W. & Yang, J. C. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427, 252-256 (2004).
77. Vigneron, N. et al. An antigenic peptide produced by peptide splicing in the proteasome. Science 304, 587-590 (2004).
78. Yin, Y., Manoury, B. & Fahraeus, R. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 301, 1371-1374 (2003).
79. Levitskaya, J. et al. Inhibiton of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375, 685-688 (1995).
80. Bachmair, A., Finley, D. & Varshavsky, A. In vivo half-life of a protein is a function of its amino-terminal residue. Science 234, 179-186 (1986).
81. Pines, J. Mitosis: a matter of getting rid of the right protein at the right time. Trends Cell. Biol. 16, 55-63 (2006).
82. Tsuda, H., Tokunaga, F., Nagamitsu, H. & Koide, T. Characterization of endoplasmic reticulum-associated degradation of a protein S mutant identified in a family of quantitative protein S deficiency. Thromb. Res. 117, 323-331 (2006).
83. Liu, Y. & Chang, A. Quality control of a mutant plasma membrane ATPase: ubiquitylation prevents cell-surface stability. J. Cell Sci. 119, 360-369 (2006).
84. Chen, Y., Yee, D. & Magnuson, T. A novel mouse Smad4 mutation reduces protein stability and wild-type protein levels. Mamm. Genome. 17, 211-219 (2006).
85. Riess, N. P. et al. Trapping of normal EB1 ligands in aggresomes formed by an EB1 deletion mutant. BMC Cell. Biol. 6, 17 (2005).
86. Sekijima, Y. et al. The biological and chemical basis for tissue-selective amyloid disease. Cell 121, 73-85 (2005).
87. Ratovitski, T. et al. Variation in the biochemical/biophysical properties of mutant superoxide dismutase 1 enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds. Hum. Mol. Genet. 8, 1451-1460 (1999).
88. Katayama, K. et al. Identification of a novel amino acid deletion mutation and a very rare single nucleotide variant in a Japanese family with type I antithrombin deficiency. Thromb. Res. 116, 215-221 (2005).
89. Kittanakom, S., Cordat, E., Akkarapatumwong, V., Yenchitsomanus, P. T. & Reithmeier, R. A. Trafficking defects of a novel autosomal recessive distal renal tubular acidosis mutant (S773P) of the human kidney anion exchanger (kAE1). J. Biol. Chem. 279, 40960-40971 (2004).
90. Olzmann, J. A. et al. Familial Parkinson's disease-associated L166P mutation disrupts DJ-1 protein folding and function. J. Biol. Chem. 279, 8506-8515 (2004).